

File 1644

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG

Serial No.: 09/127,138

Filed: July 31, 1998

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL
COMPOSITIONS, METHODS
AND APPLICATIONS TO
TREATMENT OF HUMAN
DISEASE

Art Unit: 1644

Examiner: Unassigned



I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

04/08/99
Date

Kathy Holloway
Kathy Holloway

RECEIVED

TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Transmitted herewith are a Supplemental Information Disclosure Statement, Form PTO-1449 (1 page), and Statement in accordance with 37 C.R.F. §1.97(e), for filing in connection with the above-identified application. The Statement applies to the reference listed on Form PTO-1449 provided herewith. Since this Supplemental Information Disclosure Statement is accompanied by a Statement, no fee should be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 08-1641.

(X) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 08-1641. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE

By:

Stephanie L. Seidman
Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E

Address all correspondence to:

HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square,
La Jolla, California 92037
Telephone: (619) 450-8400
EMAIL sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG, MICHEAL L.

Serial No.: 09/127,138

Filed: July 31, 1998

For: AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE

Art Unit: 1644

Examiner:



I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C.
20231, on this date.

Date

04/08/99 *Kathy Holloway*

Kathy Holloway

**STATEMENT FOR SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97(e)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

- 1) This Statement is being made for the Supplemental Information Disclosure Statement accompanying this Statement.
- 2) I, Stephanie Seidman, certify that no item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to my knowledge after making reasonable inquiry, no item of information contained in the Supplemental Information Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement.

**U.S.S.N. 09/127,138
GRUENBERG
STATEMENT**

3) The person making this Statement is an attorney of record in the above-captioned application and signs below on the basis of information in the attorney's file.

* * *

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No.
Address all correspondence to:
Stephanie Seidman, Esq.
HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square, 7th Floor
La Jolla, California 92037-9103
Telephone: (619) 450-8400
Facsimile: (619) 450-8499
EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG

Serial No.: 09/127,138

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL
THERAPY: CELL COMPOSITIONS,
METHODS AND APPLICATIONS TO
TREATMENT OF HUMAN DISEASE*

Art Unit: 1644

Examiner: Unassigned



I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231, on this date.

04/08/99
Date


Kathy Holloway

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
IN ACCORDANCE WITH 37 C.F.R. § 1.97(c)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 C.F.R. § 1.97(c) and includes a Statement in accordance with 37 C.R.F. § 1.97(e). The Statement applies to the reference listed on Form PTO-1449 (1 page) provided herewith. Since this Supplemental Information Disclosure Statement is accompanied by a Statement, no fee should be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 08-1641.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98. Form PTO-1449 is provided herewith. A copy of the reference listed on the Form PTO-1449 is not provided herewith as it has been previously provided in connection with U.S. Serial No. 08/700,565, which claims priority of Provisional U.S. Application Serial No.

U.S.S.N. 09/127,138
GRUENBERG
INFORMATION DISCLOSURE STATEMENT

60/044,693 (converted from 08/506,668), and which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120.


No item of information contained in the Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and no item of information contained in the Supplemental Information Statement was known to any individual designated in §1.56(c) more than three months prior to the filing of the Supplemental Information Disclosure Statement. The document that is cited in connection with this application is in the English language. Hence, in accordance with the requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed item is necessary.

Although this document is made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Applicant respectfully requests that the Examiner review the foregoing references and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE

By:


Stephanie L. Seidman
Registration No. 33,779

Attorney Docket No. 24731-500E
Address all correspondence to:
HELLER, EHRMAN, WHITE & McAULIFFE
4250 Executive Square, Suite 700,
La Jolla, California 92037
Telephone: (619) 450-8403
EMAIL sseidman@hewm.com